EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

Biologics for Chronic Rhinosinusitis With Nasal Polyposis: Current Landscape and Future Directions

Jerlon Chiu, Judd Fastenberg, Charles Tong iD, Brianne Navetta-Modrov, Sonya Marcus iD

Laryngoscope Investigative Otolaryngology · 2025-10 · 10 (5)

DOI: 10.1002/lio2.70282 ↗

At a glance

Übersichtsarbeit in Laryngoscope Investigative Otolaryngology, published online on 2025-10-18. Written by Jerlon Chiu and 4 co-authors. Institution: Division of Otolaryngology-Head & Neck Surgery Stony Brook University Stony Brook New York USA. Cited 19 times so far (Crossref); 33 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a type 2 inflammatory disease that often persists despite medical and surgical treatments. Recently, biologic therapies targeting key cytokines—interleukin (IL)‐4, IL‐5, IL‐13—and immunoglobulin E (IgE) have transformed management options for patients with severe or recurrent disease. Dupilumab, omalizumab, and mepolizumab are FDA‐approved biologics proven to reduce polyp size, improve symptoms, and enhance quality of life in clinical trials. Guidelines now endorse the use of biologics in select patients with evidence of type 2 inflammation and inadequate control after standard treatments. However, challenges remain, including high costs, uncertain treatment duration, lack of direct comparisons, and absence of validated biomarkers to guide selection. Additionally, the optimal role of biologics relative to endoscopic sinus surgery is not yet clear. Emerging therapies—including long‐acting anti–IL‐5 agents and new targets like TSLP and IL‐33—may further broaden options. Research is also needed for patients with non‐type two inflammation who respond poorly to current treatments. Ultimately, personalized approaches based on disease phenotype and biomarkers are crucial to optimizing outcomes. This review summarizes current evidence and future directions for biologic use in CRSwNP, focusing on efficacy, patient selection, surgery integration, and precision medicine opportunities.

Subjects

Author keywords

biologicschronic rhinosinusitisnasal polyposis

Authors and institutions

  • Division of Otolaryngology-Head & Neck Surgery Stony Brook University Stony Brook New York USA.
  • Northwell New Hyde Park New York USA.
  • Department of Otolaryngology-Head and Neck Surgery Zucker School of Medicine at Hofstra/Northwell Hempstead New York USA.
  • Department of Medicine Stony Brook University Stony Brook New York USA.

ORCID profiles: Charles Tong, Sonya Marcus

Cite

APA

Chiu, J., Fastenberg, J., Tong, C., Navetta-Modrov, B., & Marcus, S. (2025). Biologics for Chronic Rhinosinusitis With Nasal Polyposis: Current Landscape and Future Directions. Laryngoscope Investigative Otolaryngology, 10(5). https://doi.org/10.1002/lio2.70282

Vancouver

Chiu J, Fastenberg J, Tong C, Navetta-Modrov B, Marcus S. Biologics for Chronic Rhinosinusitis With Nasal Polyposis: Current Landscape and Future Directions. Laryngoscope Investigative Otolaryngology. 2025;10(5). doi:10.1002/lio2.70282

BibTeX
@article{Chiu2025,
  author = {Chiu, Jerlon and Fastenberg, Judd and Tong, Charles and Navetta-Modrov, Brianne and Marcus, Sonya},
  title = {Biologics for Chronic Rhinosinusitis With Nasal Polyposis: Current Landscape and Future Directions},
  journal = {Laryngoscope Investigative Otolaryngology},
  year = {2025},
  volume = {10},
  number = {5},
  doi = {10.1002/lio2.70282}
}
Start for free →